T-DXd was approved in China in October 2024 for HER2-mutant NSCLC, marking a significant step forward in expanding treatment options for this challenging subgroup beyond traditional chemotherapy and non-targeted approaches. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.